Forte Biosciences Shares Surge After $2.2 Billion Acquisition Deal with argenx

Shares of Forte Biosciences experienced a significant surge following the announcement of a $2.2 billion acquisition deal with biotechnology company argenx. The agreement includes a specific premium per share for Forte's existing shareholders, substantially increasing the company's valuation. The acquisition is seen as part of argenx's strategy to expand its portfolio. Forte Biosciences is known for developing treatments for immune system diseases, and this deal will strengthen argenx's presence in this area. Market analysts note that the deal will create synergies for both companies. Forte's existing drug candidates and research platform, combined with argenx's resources, offer potential for faster clinical development and commercialization. The completion of the deal is subject to regulatory approvals and shareholder votes. The process is expected to conclude within 2024. Forte shares saw a marked increase in trading volume following the news. This is not investment advice.